|
Diffuse Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The analysis of the mutation in the isocitrate dehydrogenase (IDH) genes IDH1 and IDH2 has provided important diagnostic and prognostic information for patients affected by diffuse glioma (i.e., the presence of the mutation has been related to an increased survival rate).
|
31526886 |
2020 |
|
Diffuse Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thirty cases of IDH1 (R132H)-mutant diffuse glioma, which were originally assessed on FSs, were retrieved.
|
30221786 |
2019 |
|
Diffuse Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
GCA is a variant of IDH-wildtype diffuse glioma with aggressive behavior irrespective of grade and extent of granular cell morphology, and with molecular genetic features corresponding to primary glioblastoma.
|
30222900 |
2019 |
|
Diffuse Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, detection of the genetic status of IDH1 before therapy massively expands the utility of immunohistochemistry to accurately distinguish patients with a less aggressive and radiosensitive IDH1-mutant diffuse glioma suitable for radiotherapy from those with a more aggressive IDH1-wildtype diffuse glioma who might benefit from an individually intensified therapy comprising radiotherapy and alternative medical treatments.
|
31242696 |
2019 |
|
Diffuse Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy.
|
29172136 |
2018 |
|
Diffuse Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a resource-limited set-up, histology with IHC (IDH1(R132H) and ATRX) form the baseline to reasonably derive four histomolecular subgroups of diffuse glioma.
|
28801347 |
2018 |
|
Diffuse Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?
|
28782849 |
2017 |
|
Diffuse Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Correlation of immune phenotype with IDH mutation in diffuse glioma.
|
28531337 |
2017 |
|
Diffuse Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Gain-of-function mutations in isocitrate dehydrogenases (IDH1 and IDH2) promote diffuse glioma formation through epigenetic reprogramming of a number of genes, including immune-related genes.
|
27116977 |
2016 |
|
Diffuse Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A subtype of IDH mutant glioma was associated with DNA demethylation and poor outcome; a group of IDH-wild-type diffuse glioma showed molecular similarity to pilocytic astrocytoma and relatively favorable survival.
|
26824661 |
2016 |
|
Diffuse Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we characterized IDH-1R132H mut status in a cohort of 670 adult patients with different WHO2007 grades of diffuse glioma.
|
27120786 |
2016 |
|
Diffuse Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations.
|
25980633 |
2015 |
|
Diffuse Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additional genomic and epigenomic signatures are generally nonoverlapping between IDH-mutant and IDH wild-type diffuse glioma, and despite comparable histopathology, IDH-mutant gliomas can be considered as biologically distinct from IDH wild-type gliomas.
|
25398843 |
2014 |
|
Diffuse Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Complete 1p/19q co-deletion, MGMT promoter methylation and/or IDH1 mutation generally signified a better prognosis for patients with a diffuse glioma including glioblastoma.
|
23429602 |
2013 |
|
Diffuse Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations involving isocitrate dehydrogenase 1 (IDH1) have recently emerged as important diagnostic and prognostic markers in DG.
|
22197544 |
2012 |
|
Diffuse Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The absence of mutant IDH1 R132H protein expression in AG may help further distinguish this unique neoplasm from diffuse glioma.
|
22445362 |
2012 |
|
Diffuse Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Because IDH1 does not belong to a traditional oncogenic pathway and is specifically and commonly mutated in gliomas, the altered enzymatic activity of IDH1 may provide a fundamentally new understanding of diffuse glioma.
|
20615753 |
2011 |